Dr. Marcus Säemann präsentiert seine Highlights vom ERA 2025 in Wien.

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

https://www.nejm.org/doi/abs/10.1056/NEJMoa2410659

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

https://www.nejm.org/doi/full/10.1056/NEJMoa2501006

ARO-C3, an investigational RNAi Therapeutic Targeting Complement C3, Reduces Proteinuria, Hematuria, andComplement Activity in IgAN Patients

https://ir.arrowheadpharma.com/static-files/71ace783-f6cd-47ac-b9a5-5809c13b70f1

Pegcetacoplan for C3G and primary (idiopathic) IC-MPGN: 52-week results from the phase 3 VALIANT trial show sustained efficacy

https://sciencelibrary.sobi.com/sites/default/files/documents/Fakhouri_VALIANT_52w_ERA2025_Oral.pdf

Impact of acute eGFR dips and markers of disease severity on effects of empagliflozin on acute kidney outcome

https://era-apps.m-anage.com/era25/en-GB/pag/presentation/505078#xd_co_f=NGQ1M2RkMjgtOTdjOC00NjgwLTk4NjQtZjJmZTUxYmJkNTcw~

https://www.youtube.com/watch?v=bX2Xtj_8mkg

https://www.renalandurologynews.com/reports/egfr-dip-empagliflozin-initiation-acute-renal-risks-treatment/#:~:text=Dr%20Staplin's%20team%20concluded%2C%20%E2%80%9CEmpagliflozin,of%20these%20diseases'%20severity.%E2%80%9D

Dieser Podcast wurde mit freundlicher Unterstützung von Boehringer Ingelheim RCV GmbH & Co realisiert.

Support the show